An interventional study of Oziva Bioactive Gluta Fizzy Effervescent Tablets 4.1 g containing Glutathione and Placebo Effervescent Tablets 4.1 g in Hyperpigmentation, sponsored by NovoBliss Research Pvt Ltd. Completed at 1 site in India. Open to participants aged 21 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by NovoBliss Research Pvt Ltd · Not applicable, Interventional, and Supportive care
This is a randomized, double-blinded, single-centre, two-arms, placebo-controlled, prospective study to evaluate clinical safety, efficacy and in-use tolerability of Test Product i.e. Oziva Bioactive Gluta Fizzy Effervescent tablets in subjects with facial hyperpigmentation and dark spots.
A total of 60 Indian Subjects (30 Subjects per Test Product), including males and non-pregnant, non-lactating females aged between 21 and 55 years (inclusive). Indian Subjects with a Fitzpatrick skin type of III to VI must present with facial hyperpigmentation and dark spots such as tan, pimple marks, sunspots, age spots, uneven skin tone on both side of face at baseline. Participants will be randomized in a 1:1 ratio to received either test Product A or test Product B. the study aims to complete evaluation for 50 Indian Subjects (25 Subjects per Test Product).
The potential subjects will be screened as per the inclusion and exclusion criteria only after obtaining written informed consent from the subjects. Subjects will be contacted telephonically by recruiting department prior to the screening.
There will be total of 3 visits during the study. The duration of the study will be 90 Days (12 weeks) from the enrolment. Subjects will be instructed to visit the facility as per below visits:
127 studies on the registry are indexed under Hyperpigmentation; 28 are open to participants now.
This study's enrollment of 62 is above the median of 32 across 113 interventional studies indexed under Hyperpigmentation.
Browse Hyperpigmentation studies →NovoBliss Research Pvt Ltd is the lead sponsor of 47 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1) Age: 21 to 55 years (both inclusive) at the time of consent. 2) Sex: Adult male and female having facial hyperpigmentation and dark spots such as tan, pimple marks, sunspots, age spots, uneven skin tone on both side of face.
3) Females of should have a self-reported negative urine pregnancy test at the time of screening visit.
4) Subjects with Fitzpatrick Skin Types III to VI, indicating moderate to dark skin tones.
5) Subjects should not have used any cosmetic, nutraceutical or therapeutic products for skin ageing in last 3 months.
6) Subjects must be willing to stop using any cosmetics or any medical products for skin ageing for the duration of the study.
7) Subjects are not allowed to participate in any other study until this study is complete.
8) Subjects must be willing and able to follow the study directions and to return for all specified visits with the product.
9) Subjects must agree to record each use of the test products in the subject's diary card on daily basis.
10) Subjects must agree to record medication use during the study
Exclusion Criteria:
1) Subjects who are on for last six months. 2) Subjects who have used any cosmetic, nutraceutical or therapeutic products for skin last three months.
3) Subjects who are on product which contains kojic acid, glycolic acid, niacinamide, alpha arbutin, Vitamin C and other skin ageing product.
4) Subjects with other dermatologic diseases whose presence or products could interfere with the assessment of study.
5) Subjects that are pregnant and/or breastfeeding. 6) The subject has a known allergy or sensitivity to product ingredients. 7) Subjects if do not agree to limit sun exposure to affected areas such as face during prolonged sun exposure.
8) The subject has any other skin conditions i.e. cuts, scratches, ring worms, etc. which in the opinion of the Investigator, will interfere with the study results or will create undue risk for the subject.
9) The subject has any of the conditions or factors that the Investigator believes may affect the response of the skin or the interpretation of the test results.
10) The subject is currently taking or has taken any medication, which the Investigator believes may influence the interpretation of the data.
11) Any other condition which could warrant exclusion from the study, as per the dermatologist's/investigator's discretion.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends. Frequency: Once Daily Route of administration: Oral Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight
Other: Oziva Bioactive Gluta Fizzy Effervescent Tablets 4.1 g containing Glutathione
Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends. Frequency: Once Daily Route of administration: Oral Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight.
Other: Placebo Effervescent Tablets 4.1 g
Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends. Frequency: Once Daily Route of administration: Oral Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight
Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends. Frequency: Once Daily Route of administration: Oral Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight
Change in skin radiance measured by Glossymeter (Percent)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Change in skin pigmentation and dark spots measured by Mexameter® MX 18 (Percent)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Change in skin elasticity and firmness (R0 and R2 parameters) measured by Cutometer® Dual MPA 580 (Percentage)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Change in skin hydration measured by Corneometer® CM 825 (Percentage)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Change in oxidative stress marker Superoxide Dismutase (SOD) levels (U/mL)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 90 (±2 days)
Change in inflammatory markers (C-Reactive Protein and Interleukin-6 [IL-6]) [pg/mL]
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 90 (±2 days)
Change in skin color parameters (L*, a*, b*, and ITA) measured by Skin Colorimeter CL 400 (values; ITA in degrees)
Comparison of changes within each test product group and between product groups.
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Change in spot color intensity, average size (mm2) and number, pigmentation intensity, and contrast measured by Dermatological Evaluation using Modified Griffiths 10-point Scale
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Change in pigmentation intensity, spot surface area (mm2), and skin radiance measured by Image-Pro Analysis
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Change in melasma severity measured by Dermatological Evaluation using Melasma Area and Severity Index (MASI) (percentage)
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Change in visual skin appearance from facial photographs using Nikon Digital Camera D3300 or equivalent
Comparison of changes within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Change in subject-reported product perception (skin appearance, radiance, pigment reduction, glow, blemishes, and dark patch reduction) assessed by questionnaire
Comparison of responses within each test product group and between product groups
Time frame: Baseline (Day 1) to Day 45 (±2 days) and Day 90 (±2 days)
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NovoBliss Research Pvt Ltd